Publication date: Jan 28, 2025
Background/Objectives: Neonatal hypoxic-ischemic encephalopathy (HIE) due to perinatal complications remains an important pathology with a significant burden for neonates, families, and the healthcare system. Resuscitation and simulation team training are key elements in increasing patient safety. In this retrospective cohort study, we evaluated whether regular constant training of all personnel working in delivery rooms in South Tyrol improved the outcome of neonates with HIE. Methods: We retrospectively analyzed three groups of neonates with moderate to severe HIE who required therapeutic hypothermia. The first group included infants born before the systematic introduction of training and was compared to the second group, which included infants born after three years of regular training. A third group, which included infants born after the SARS-CoV-2 pandemic, was compared with the previous two to evaluate retention of skills and the long-term effect of our training program. Results: Over the three study periods, mortality decreased from 41. 2% to 0% and 14. 3%, respectively. There was also a significant reduction of patients with subclincal seizures detected only through EEG, from 47. 1% in the first period to 43. 7% and 14. 3% in the second and third study periods, respectively. Clinical manifestations of seizures decreased significantly from 47. 1% to 37. 5% and 10. 7%, respectively, as well as severe brain lesions in ultrasound (US) and MRI. Conclusions: In this study, constant and regular simulation training for all birth attendants significantly decreases mortality and improves the outcome in neonates with moderate to severe HIE. This positive effect seems to last even after a one-year period during which training sessions could not be performed due to the COVID-19 pandemic.
Open Access PDF
Concepts | Keywords |
---|---|
Healthcare | hypoxic ischemic encephalopathy |
Mri | perinatal asphyxia |
Pandemic | simulation |
Training | team training |
Tyrol |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Hypoxic-Ischemic Encephalopathy |
disease | MESH | complications |
disease | MESH | hypothermia |
disease | MESH | seizures |
disease | MESH | COVID-19 pandemic |
drug | DRUGBANK | Spectinomycin |
disease | MESH | asphyxia |
disease | MESH | live births |
drug | DRUGBANK | Oxygen |
disease | IDO | blood |
disease | MESH | oxidative stress |
disease | IDO | production |
disease | MESH | death |
disease | MESH | inflammation |
disease | MESH | hypoxemia |
disease | MESH | ischemia |
disease | MESH | morbidity |
disease | MESH | cerebral palsy |
disease | MESH | epilepsy |
disease | MESH | emergencies |
drug | DRUGBANK | Etoperidone |
drug | DRUGBANK | Trestolone |
disease | MESH | fetal distress |
disease | MESH | shoulder dystocia |
drug | DRUGBANK | Acetohydroxamic acid |
drug | DRUGBANK | Methionine |
drug | DRUGBANK | Pentaerythritol tetranitrate |
drug | DRUGBANK | Creatinine |
disease | MESH | thrombocytopenia |
disease | MESH | bradycardia |
disease | MESH | acidosis |
disease | MESH | subclinical seizures |
disease | MESH | Status marmoratus |
disease | IDO | intervention |